GC Biopharma Corp.

As of June 30, 2026, GC Biopharma Corp. carries a market capitalization of 1.37T, placing it among publicly traded companies globally. Its enterprise value stands at 2.36T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

GC Biopharma Corp.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, GC Biopharma Corp. has 11.41M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.70, and the price-to-book ratio stands at 1.11.

As of June 30, 2026, GC Biopharma Corp. trades at an EV/EBITDA multiple of 17.73 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 49.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.36T versus a market cap of 1.37T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GC Biopharma Corp. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 70.79, indicating elevated leverage, while an interest coverage ratio of 2.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GC Biopharma Corp. posted a negative return on equity (ROE) of -3.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.69, reflecting losses generated across the asset base. The company generates approximately 835.01M in revenue per employee across its workforce of 2,352.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.63 indicates how many times GC Biopharma Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, GC Biopharma Corp. recorded 5.26B in income tax expense. The company reported a pretax loss of -58.19B and -49.90B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, GC Biopharma Corp.'s stock has gained approximately 2.64% over the past 52 weeks. The 50-day moving average sits at 127,292.00, while the 200-day moving average is 138,865.00.

Over the twelve months ended June 30, 2026, GC Biopharma Corp. generated 1.96T in revenue and converted that into -49.90B in net income, yielding earnings per share of -5,559.49. EBITDA reached 132.84B, while operating income came in at 47.28B.

As of June 30, 2026, GC Biopharma Corp. holds 44.66B in cash and equivalents against 938.85B in total debt, resulting in a net debt position of 790.60B. Total book value stands at 1.24T, with working capital of 348.70B providing operational flexibility.

GC Biopharma Corp. produced 184.28B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -128.00B in capital expenditures, free cash flow totaled 56.28B - equivalent to 4,931.49 per share.

Over the twelve months ended June 30, 2026, GC Biopharma Corp. posted a gross margin of 26.40, reflecting its pricing power and cost economics. The operating margin of 2.41 and net profit margin of -2.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, GC Biopharma Corp. paid dividends of 1,719.91 per share. The dividend payout ratio of -25.49 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to GC Biopharma Corp. shareholders.

GC Biopharma Corp.'s most recent stock split took place on June 7, 2013 with a 20:21 split ratio.

As of June 30, 2026, GC Biopharma Corp. has an Altman Z-Score of 2.02, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.